Physician profile
Scott R Dunn
NPI 1952308405
$586.30
in general payments reported to CMS, 2019-2025
14 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $37.94 · 2021: $132 · 2023: $67.33 · 2024: $99.58 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $187.35 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $61.57 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $48.51 | 2021-2025 | Mounjaro, Zepbound |
| Sanofi Pasteur INC. | $47.08 | 2019-2021 | |
| Coopersurgical, INC. | $46.72 | 2024 | Paragard T 380a |
| Pfizer INC. | $43.00 | 2019-2023 | |
| Glaxosmithkline, LLC. | $26.26 | 2019-2020 | |
| Medtronic, INC. | $24.67 | 2025 | Minimed 780g |
| Insulet Corporation | $23.08 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $21.66 | 2023 | Eliquis |
| Dexcom, INC. | $16.95 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $15.38 | 2025 | Freestyle Libre 3 |
| Allergan, INC. | $12.63 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.